Selecta Biosciences, Inc. (SELB)

NASDAQ: SELB · IEX Real-Time Price · USD
2.39 -0.11 (-4.40%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap278.79M
Revenue (ttm)67.09M
Net Income (ttm)-53.37M
Shares Out116.65M
EPS (ttm)-0.48
PE Ration/a
Forward PE69.93
Dividendn/a
Ex-Dividend Daten/a
Volume1,157,389
Open2.46
Previous Close2.50
Day's Range2.37 - 2.52
52-Week Range2.37 - 5.70
Beta1.04
AnalystsStrong Buy
Price Target8.83 (+269.5%)
Earnings Daten/a

About SELB

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropat...

IndustryBiotechnology
IPO DateJun 22, 2016
CEOCarsten Brunn
Employees43
Stock ExchangeNASDAQ
Ticker SymbolSELB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for SELB stock is "Strong Buy." The 12-month stock price forecast is 8.83, which is an increase of 269.46% from the latest price.

Price Target
$8.83
(269.46% upside)
Analyst Consensus: Strong Buy

News

Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids

WATERTOWN, Mass. and BOSTON, Jan. 10, 2022 /PRNewswire/ --  Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic ...

Other symbols:DNA
1 week ago - PRNewsWire

Selecta Biosciences to Participate at the 2022 H.C. Wainwright BioConnect Conference

WATERTOWN, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...

2 weeks ago - GlobeNewsWire

Selecta Biosciences to Participate at the LifeSci Partners 11th Annual Corporate Access Event

WATERTOWN, Mass., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...

3 weeks ago - GlobeNewsWire

4 Penny Stocks Analysts Say To Buy Now & Targets Up To 117%

4 penny stocks with bullish price targets & buy ratings from analysts. The post 4 Penny Stocks Analysts Say To Buy Now & Targets Up To 117% appeared first on Penny Stocks to Buy, Picks, News and Informa...

Other symbols:ENSCIINNOPK
1 month ago - PennyStocks

Best Penny Stocks To Buy? 5 Short Squeeze Stocks To Watch Right Now

5 penny stocks with high short interest to add to your watch list in December. The post Best Penny Stocks To Buy?

Other symbols:IINNPLXSPRBTELL
1 month ago - PennyStocks

10 Penny Stocks To Buy In December According To Insiders

Corporate insiders buy penny stocks & these 10 are getting purchased in December 2021. The post 10 Penny Stocks To Buy In December According To Insiders appeared first on Penny Stocks to Buy, Picks, New...

1 month ago - PennyStocks

Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study evaluating SEL-212 for chroni...

STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of enrolment for DISSOLVE I, t...

1 month ago - PRNewsWire

Selecta Biosciences and Sobi Announce Completion of Enrollment in DISSOLVE Phase 3 Study Evaluating SEL-212 for Chron...

-DISSOLVE program on track with 12-month study fully enrolled- -DISSOLVE II on track for full enrollment in early 2022- -Top-line data from Phase 3 DISSOLVE program expected in H2 2022-

1 month ago - GlobeNewsWire

Selecta (SELB) Down on FDA's Clinical Hold on Phase I/II Study

The FDA issues a clinical hold on Selecta's (SELB) phase I/II study evaluating SEL-302 for the treatment of patients with methylmalonic acidemia. Shares down in after-hours trading.

1 month ago - Zacks Investment Research

Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia

-U.S. FDA has issued a clinical hold on Phase 1/2 Clinical Trial of SEL-302 due to CMC related questions- -U.S. FDA has issued a clinical hold on Phase 1/2 Clinical Trial of SEL-302 due to CMC related q...

1 month ago - GlobeNewsWire

Selecta Biosciences to Participate in Jefferies Virtual London Healthcare Conference

WATERTOWN, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...

2 months ago - GlobeNewsWire

Selecta Biosciences, Inc. (SELB) Reports Q3 Loss, Tops Revenue Estimates

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -128.57% and 82.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the...

2 months ago - Zacks Investment Research

Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update

-Established four strategic collaborations to advance next generation therapeutics and maximize the potential of ImmTOR platform-

2 months ago - GlobeNewsWire

Selecta Biosciences Posts Encouraging Data For ImmTOR Platform

Selecta Biosciences Inc (NASDAQ: SELB) announced top-line results from the Phase 1 study evaluating the ImmTOR platform to mitigate the formation of neutralizing antibodies against an adeno-associated v...

2 months ago - Benzinga

Selecta Biosciences Announces Top Line Data from the Phase I SEL-399 AAV Empty Capsid Study, Highlighting Potential B...

- At day 30, of subjects in the 0.3mg/kg ImmTOR cohort, 100% showed NAb titers of ≤ 1:25, and 67% showed NAb titers of ≤ 1:5 -

2 months ago - GlobeNewsWire

Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide B...

WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...

2 months ago - GlobeNewsWire

Selecta Biosciences, Inc. (SELB) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Selecta Biosciences, Inc. (SELB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments

Selecta Biosciences Inc (NASDAQ: SELB) and Ginkgo Bioworks Holdings Inc (NYSE: DNA) have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases.  The partne...

Other symbols:DNA
2 months ago - Benzinga

Selecta Biosciences and Ginkgo Bioworks Announce Partnership to Advance Treatments for Orphan and Rare Diseases

BOSTON and WATERTOWN, Mass., Oct. 26, 2021 /PRNewswire/ -- Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic t...

Other symbols:DNA
2 months ago - PRNewsWire

Selecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene The...

- Selecta obtains from Genovis exclusive worldwide rights to Xork, a differentiated IgG protease -

3 months ago - GlobeNewsWire

Selecta Biosciences to Participate in Jefferies Virtual Gene Therapy/Editing Summit

WATERTOWN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...

3 months ago - GlobeNewsWire

Selecta Biosciences to Present New Data for the ImmTOR™ platform at the ESGCT 28th Annual Congress

WATERTOWN, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...

3 months ago - GlobeNewsWire

5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets

Will these penny stocks meet analysts' expectations? The post 5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets appeared first on Penny Stocks to Buy, Picks, News and Information | Penny...

Other symbols:AIKINMTRPROGTRVI
3 months ago - PennyStocks

Selecta Biosciences Announces Strategic Licensing Agreement with Takeda to Develop Next-Generation Gene Therapies for...

Selecta's ImmTOR™ platform enhances transgene expression and addresses adeno-associated virus (AAV) vector immunogenicity constraints to deliver transformative therapies Selecta's ImmTOR™ platform enhan...

3 months ago - GlobeNewsWire

Selecta Biosciences to Participate in Cantor Virtual Global Healthcare Conference

WATERTOWN, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapi...

4 months ago - GlobeNewsWire